登录新浪财经APP 搜索【信披】查看更多考评等级 嘉兴中润光学科技股份有限公司 2024年限制性股票激励计划第一个归属期归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为774,000股。 本次股票上市流通总数为774,000股。 ● 本次股票上市流通日期为2025年9月17日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司相关业务 规定，嘉兴中润光学科技股份有限公司（以下简称"公司"）于近日收到中国证券登记结算有限责任公司 上海分公司出具的《证券变更登记证明》，公司完成了2024年限制性股票激励计划第一个归属期的股份 登记工作。现将有关情况公告如下： 证券代码：688307 证券简称：中润光学 公告编号：2025-043 一、本次限制性股票归属的决策程序及相关信息披露 （1）2024年8月9日，公司第二届董事会第三次会议审议通过了《关于〈2024年限制性股票激励计划 （草案）〉及其 ...

证券代码：688307 证券简称：中润光学 公告编号：2025-043 嘉兴中润光学科技股份有限公司 2024 年限制性股票激励计划第一个归属期归属结果 暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，嘉兴中润光学科技股份有限公司（以下简称"公 司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登 记证明》，公司完成了 2024 年限制性股票激励计划第一个归属期的股份登记工作。 现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （1）2024 年 8 月 9 日，公司第二届董事会第三次会议审议通过了《关于<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于<2024 年限制性股票激 励计划实施考核管理办法>的议案》《关于提请公司股东大会授权董事会办理公司 2024 年限制性股票激励计划有关事项的议案》。 同日，公司第二届监事会第三次会议审议通 ...

嘉兴中润光学科技股份有限公司公告2024年限制性股票激励计划第一个归属期归属结果及股票上市情 况。本次归属激励对象95人，归属股份77.4万股，占获授限制性股票数量的40%，股票来源为向激励对 象定向发行A股普通股。归属股票将于2025年9月17日上市流通，上市流通股数77.4万股。本次归属后公 司股本总数由8800万股增至8877.4万股，控股股东及实际控制人未变。天健会计师事务所已完成验资， 归属未对公司最近一期财务状况及经营成果构成重大影响。 ...

证券代码：688307 证券简称：中润光学 公告编号：2025-042 嘉兴中润光学科技股份有限公司 关于变更签字会计师的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉兴中润光学科技股份有限公司（以下简称"公司"）于 2025 年 3 月 28 日召开了第二届董事会第七次会议，于 2025 年 4 月 18 日召开了 2024 年年度股 东大会，审议通过了《关于续聘 2025 年度会计师事务所的议案》，同意聘请天 健会计师事务所（特殊普通合伙）（以下简称"天健所"）为公司 2025 年度财 务报表及内部控制审计机构。具体内容详见公司于 2025 年 3 月 29 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于续聘 2025 年度会计师事务所的公 告》（公告编号 2025-008）。 近日，公司收到天健所送达的《关于变更签字注册会计师的函》，现将相关 变更情况告知如下： 一、本次签字会计师变更的基本情况 天健所作为公司 2025 年度财务报表和 2025 年末财务报告内部控制审计机 构，原委派韦 ...

Core Viewpoint - Zhongrun Optics (688307) reported a revenue increase of 29.73% year-on-year for the first half of 2025, with a total revenue of 250 million yuan and a net profit of 20.56 million yuan, reflecting a modest growth of 0.98% [1] Financial Performance - Total revenue for the first half of 2025 reached 250 million yuan, up from 192 million yuan in the same period of 2024, marking a 29.73% increase [1] - Net profit attributable to shareholders was 20.56 million yuan, slightly up from 20.36 million yuan, indicating a 0.98% growth [1] - The second quarter alone saw a revenue of 138 million yuan, a 21.69% increase year-on-year, with a net profit of 10.27 million yuan, up 10.69% [1] - The gross profit margin was 32.33%, down 0.94% from the previous year, while the net profit margin decreased by 19.64% to 8.52% [1] - Total operating expenses (sales, management, and financial expenses) amounted to 30.07 million yuan, accounting for 12.04% of revenue, an increase of 3.9% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents increased significantly by 149.81% to 405 million yuan [1] - Accounts receivable rose by 16.82% to 93.99 million yuan, with accounts receivable to net profit ratio reaching 175.92% [1][3] - Interest-bearing liabilities decreased by 38.16% to 14.93 million yuan [1] Shareholder Metrics - Earnings per share remained stable at 0.23 yuan, while the operating cash flow per share dropped significantly by 69.93% to 0.24 yuan [1] - Book value per share increased by 3.11% to 9.74 yuan [1] Business Model and Market Position - The company's return on invested capital (ROIC) was reported at 4.97%, indicating a relatively weak capital return [2] - Historical data shows a median ROIC of 10.03% since the company went public, with the lowest ROIC recorded at 4.12% in 2023 [1][2] - The company relies heavily on research and development for its business performance, necessitating further investigation into the underlying drivers of this model [2]

Group 1 - The company Zhongrun Optical (688307.SH) reported a total operating revenue of 250 million yuan for the first half of 2025, representing a year-on-year increase of 29.73% [1] - The net profit attributable to shareholders of the parent company was 20.5646 million yuan, showing a year-on-year growth of 0.98% [1] - The basic earnings per share were 0.23 yuan, and the company proposed a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - The core purpose of the foreign exchange hedging business is to mitigate risks associated with exchange rate fluctuations due to the company's expanding overseas operations and increasing foreign currency transactions [1][2] - The company plans to conduct foreign exchange hedging transactions involving various currencies, primarily including the US dollar, to protect against exchange rate risks [1][2] - The total amount for the foreign exchange hedging business is capped at 20 million USD or equivalent foreign currency, with a validity period of 12 months from the board's approval [2][5] Group 2 - The company will only engage with qualified financial institutions approved by regulatory authorities for foreign exchange hedging transactions, ensuring low counterparty risk [3][4] - A comprehensive risk management framework has been established, including internal controls and procedures to minimize operational risks associated with foreign exchange hedging [3][4] - The company will continuously monitor market prices and assess the risk exposure of foreign exchange derivatives, reporting any anomalies to management [3][4] Group 3 - The foreign exchange hedging business is aligned with the company's operational needs and aims to enhance financial stability without harming the interests of shareholders [4][6] - The board and audit committee have approved the foreign exchange hedging proposal, confirming that it meets the company's business development requirements [5][6] - The company has developed a management system for foreign exchange hedging, detailing principles, approval authority, and risk handling procedures [4][6]

北京市朝阳区建外大街丁 12 号英皇集团中心 8 层、9 层、11 层 电话/Tel.:010-50867666 传真/Fax:010-65527227 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于 嘉兴中润光学科技股份有限公司 授予价格调整、第一个归属期归属条件成就及 部分限制性股票作废事项 之 法 律 意 见 书 康达法意字【2025】第 0439 号 二零二五年八月 法律意见书 释 义 《嘉兴中润光学科技股份有限公司 2024 年限制性股票激励计划 《激励计划（草案）》 指 （草案）》 本次激励计划/本激 指 中润光学 2024 年限制性股票激励计划 励计划 《北京市康达律师事务所关于嘉兴中润光学科技股份有限公司 《证券法律业务执 指 《律师事务所证券法律业务执业规则（试行）》 业规则（试行）》 嘉兴中润光学科技股份有限公司 中华人民共和国，为本《法律意见书》之目的，不包括香港特别 中国 指 行政区、澳门 ...

Core Viewpoint - The company has announced the achievement of the first vesting period for its 2024 restricted stock incentive plan, allowing for the vesting of 774,000 shares to 95 eligible participants [1][8][12]. Group 1: Stock Incentive Plan Details - The total number of restricted stocks granted under the plan is 1,935,000 shares, representing 2.1989% of the company's total share capital of 88 million shares [1][2]. - The grant price for the restricted stocks is set at 9.91 yuan per share [1][13]. - The vesting schedule includes three periods: 40% after 12 months, 30% after 24 months, and 30% after 36 months from the grant date [2][3]. Group 2: Performance and Vesting Conditions - The performance targets for the first vesting period require a net profit of no less than 50 million yuan for the year 2024 [3][10]. - The cumulative net profit targets for subsequent periods are set at 115 million yuan for 2024-2025 and 195 million yuan for 2024-2026 [3][10]. - Individual performance assessments will determine the vesting ratio, categorized into four levels: A, B, C, and D, with A and B allowing for 100% vesting [4][11]. Group 3: Approval and Compliance - The plan was approved by the company's board and supervisory committee, with no objections raised during the public disclosure period [5][6]. - The board confirmed that the vesting conditions for the first period have been met, with a unanimous vote in favor [8][9]. - The supervisory committee has also verified that the incentive plan complies with relevant laws and regulations [12][15].

Core Viewpoint - The company announced adjustments to the 2024 restricted stock incentive plan, including changes to the grant price and the cancellation of certain unvested restricted stocks due to the departure of some incentive targets [1][4][6]. Group 1: Decision Process and Disclosure - The company held meetings of the board and supervisory committee to review and approve the incentive plan adjustments, ensuring compliance with legal and regulatory requirements [1][2][3]. - The supervisory committee verified the incentive plan details and issued relevant opinions, confirming no objections were raised during the public notice period [2][3]. Group 2: Reasons and Results of Adjustments - The adjustments were necessitated by the company's profit distribution plan, which included a cash dividend of 0.1 yuan per share, leading to a recalibration of the stock grant price [4][5]. - The adjusted grant price for the restricted stock is set at 9.91 yuan per share, down from the previous 10.36 yuan per share, after accounting for the dividend distribution [5]. Group 3: Impact of Adjustments - The adjustments to the grant price and the cancellation of certain restricted stocks are not expected to materially affect the company's financial status or operational results, nor will they impact the stability of the management team [5][6]. - The supervisory committee supports the adjustments, affirming that they align with relevant laws and regulations, and do not harm the interests of the company or its shareholders [6]. Group 4: Legal Opinions - The legal opinion from Beijing Kangda Law Firm confirms that the adjustments to the incentive plan have received necessary approvals and comply with relevant regulations [6].